Clinical trials: Graves' Ophthalmopathy
Graves' Ophthalmopathy
The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy
The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes.
- Trial name
- NCT00174057
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Bioavailability, Bioequivalence
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
- Trial name
- NCT06563856
- Testing
- TEPEZZA, EDP
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease, TED
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease
- Trial name
- NCT06126783
- Testing
- IBI311
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with…
- Trial name
- UplighTED (NCT06307626)
- Testing
- Efgartigimod PH20 SC
- Where
- 76 sites in United States, Austria and 16 more
- Volunteers
- 105 people
- Sponsor
- argenx
Graves' Disease, Graves Ophthalmopathy
Coagulation After Intravenous Methylprednisolone Administration
The alterations of coagulation and fibrinolysis parameters have been described in patients with endogenous Cushing's syndrome (CS) and those treated with glucocorticosteroids (GCs).
- Conditions
- Graves' Disease, Graves Ophthalmopathy, Blood Coagulation, Venous Thromboembolism
- Trial name
- NCT03535090
- Testing
- Methylprednisolone
- Volunteers
- 26 people
- Sponsor
- Piotr Miskiewicz
Thyroid Associated Ophthalmopathies
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152340
- Testing
- IBI311, Glucocorticoids
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease.
- Trial name
- NCT06525506
- Testing
- IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Graves Orbitopathy, Hyperthyroidism
Development of a Non-Invasive Prognostic Test for Graves Orbitopathy
The aim of this research project is to develop a non-invasive, simple, robust, and sensitive prognostic test that can identify hyperthyroidism patients who are at risk of developing Graves' Orbitopathy.
- Trial name
- GoPro (NCT07472062)
- Testing
- Schirmer's test
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Thyroid Eye Disease
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Trial name
- TED (NCT05683496)
- Testing
- lonigutamab
- Where
- 11 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- ACELYRIN Inc.
Graves Disease, Amiodarone-Induced Thyrotoxicosis
Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
The goal of this observational study is to learn about the potential differences in morbidity of thyroidectomy (removal of the thyroid gland) depending on the preoperative hormonal status.
- Conditions
- Graves Disease, Amiodarone-Induced Thyrotoxicosis, Thyroidectomy
- Trial name
- GRATES (NCT06963203)
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 486 people
- Sponsor
- Andrea Goldmann
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)
This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED: 1. β- Carotene (30 mg) 2. Vit C (100 mg) 3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU 4.
- Trial name
- NCT02393183
- Testing
- ASTED, Selenium
- Where
- Iran
- Sponsor
- Iran University of Medical Sciences
Thyroid Associated Ophthalmopathy
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
This is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages.
- Trial name
- NCT06269393
- Testing
- IBI311
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking University People's Hospital
Thyroid Eye Disease, TED
Treatment of Chronic Thyroid Eye Disease With MHB018A
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
- Trial name
- NCT07622121
- Testing
- MHB018A injection
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease
To compare the efficacy of local injections of two different types of steroid (betamethasone suspension versus triamcinolone acetate) in management of patients with thyroid-related upper lid retraction either isolated or…
- Trial name
- NCT04976816
- Testing
- peri-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- Assiut University
Graves' Disease
Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole
Evaluation of the efficacy of the combined treatment (methimazole plus selenium) in the control of hyperthyroidism as compared to methimazole alone in 30 Graves' disease (GD) untreated patients.
- Trial name
- NCT02727738
- Testing
- Selenium, Methimazole
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial…
- Trial name
- HAZEL 401 (NCT07438405)
- Testing
- AMG 732
- Where
- 8 sites in United States, Poland and 2 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Thyroid Eye Disease, Thyroid Eye Disease, TED
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease
The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED).
- Conditions
- Thyroid Eye Disease, Thyroid Eye Disease, TED, Thyroid Eye Disease (TED)
- Trial name
- NCT07308964
- Testing
- Teprotumumab Injection [Tepezza]
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Thyroid Associated Ophthalmopathy
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied.
- Trial name
- NCT03107078
- Testing
- Glucocorticoids
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jie Shen
Thyroid Eye Disease, Graves Ophthalmopathy
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy: A Randomized Control Trial.; The study aims to evaluate the response of adding selenium in patients with Graves ophthalmopathy, focusing on…
- Trial name
- NCT06413043
- Testing
- Selenium
- Where
- India
- Volunteers
- 78 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar